MINI FUTURE LONG - UNITED THERAPEUTICS Share Price

Certificat

DE000MB67VY3

Market Closed - Börse Stuttgart 20:52:19 03/07/2024 BST
19.18 EUR -5.19% Intraday chart for MINI FUTURE LONG - UNITED THERAPEUTICS
Current month+1.25%
1 month+28.44%
Date Price Change
03/07/24 19.18 -5.19%
02/07/24 20.23 -0.10%
01/07/24 20.25 +1.35%
28/06/24 19.98 -0.84%
27/06/24 20.15 -0.40%

Delayed Quote Börse Stuttgart

Last update July 03, 2024 at 08:52 pm

More quotes

Static data

Product typeKnock-Out mit Stop Loss
Buy / SellCALL
Underlying UNITED THERAPEUTICS CORPORATION
Issuer Morgan Stanley
WKN MB67VY
ISINDE000MB67VY3
Date issued 11/05/2023
Strike 102.8 $
Maturity Unlimited
Parity 10 : 1
Emission price 10.76
Emission volume N/A
Settlement Barausgleich
Currency EUR

Technical Indicators

Highest since issue 20.73
Lowest since issue 10.33

Company Profile

United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.
Sector
-
More about the company

Ratings for United Therapeutics Corporation

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: United Therapeutics Corporation

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
311.2 USD
Average target price
302.5 USD
Spread / Average Target
-2.79%
Consensus